Komori
JCR Pharmaceuticals (4552) · RiskWorsened

Stable supply risks arising from manufacturing facilities and raw material suppliers

First written in FY2020. 2 of 5 entries say "Mitigated", first in FY2021. Latest entry: FY2026.

5entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020MitigatedFY2021WorsenedFY2022MitigatedFY20242020: 120202021: 120212022: 120222023: 020232024: 120242025: 020252026: 12026
Same theme, other companies

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「In particular, amid the impact of global shortages of natural resources, construction materials and electronic components resulting from new threats such as COVID-19, the situation in Russia and Ukraine, and tariff policies and associated foreign-exchange fluctuations arising from changes in the US administration, we cannot rule out impacts on plans for constructing new facilities and delivery schedules for research and production equipment.」

    Factors including changes in the US administration, tariff policies and foreign-exchange fluctuations were added to the stable-supply risk, and the possibility of impacts on delivery schedules for new facilities and research and production equipment was explicitly stated.
  2. FY2024MitigatedAnnual report

    「Accordingly, as a measure against supply uncertainty, we regularly check the availability of materials and raw materials required for manufacturing, monitor the business conditions of their suppliers, and seek to establish multiple sources wherever possible.」

    In response to the risk to stable supply arising from manufacturing facilities and raw-material suppliers, the company identified regular checks of materials and raw materials, monitoring of suppliers, and sourcing from multiple suppliers wherever possible as countermeasures.
  3. FY2022WorsenedAnnual report

    「However, technical or regulatory problems, the effects of a major disaster, political disruption arising from international conflicts, or other events at our manufacturing facilities or those of our raw-material suppliers could disrupt the stable supply of products.」

    The factors contributing to the stable-supply risk expanded to include political disruption arising from international conflicts, the situation in Russia and Ukraine, shortages of natural resources, construction materials and electronic components, and potential impacts on delivery schedules for new facility construction and equipment orders.
  4. FY2021MitigatedAnnual report

    「We have secured inventories of products, raw materials and manufacturing materials necessary for production in the near term, and no risks had materialised as of the date of preparation of this document.」

    Regarding the risk to stable supply arising from manufacturing facilities and raw-material suppliers, the company explained that it had secured inventories necessary for near-term production and that no risk had materialised as of the filing date.
  5. FY2020First statedAnnual report

    「Our group has established the production and quality-assurance systems necessary to contribute to patients’ health. However, technical, regulatory or other problems at our manufacturing facilities or those of our raw-material suppliers could disrupt the stable supply of products.」

    The company identified as a standalone item the risk to stable supply arising from technical or regulatory problems at manufacturing facilities and raw-material suppliers.
Moved together

"Commercialization, Joint Research and Licensing of J-Brain Cargo®" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1Commercialization, Joint Research and Licensing of J-Brain Cargo®2×
  3. 2Expanding revenue from core products and strengthening the product portfolio2×
  4. 3Expansion of Proprietary Biopharmaceutical Platform Technology2×
  5. 4Development of a Manufacturing and Cell Processing Center for Investigational Drugs2×
  6. 5Strengthening Compliance, Transparency and Internal Controls2×
  7. 6Developing Talent with a Spirit of Challenge and Advancing Diversity2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Stable supply risks arising from manufacturing facilities and raw material suppliers | JCR Pharmaceuticals Co.,Ltd. (4552) | Komori